Since NTCP was cloned in 1994, its function has been studied extensively, while a number of SLC10A1 genetic variants have been identified in humans^[3], such as c.800C>T (p. Ser267Phe), c.263T>C (p. Ile88Thr), c.595A>C (p. Ser199Arg), c.755G>A (p.Arg252His), c.615_618del (p.Ser206Profs*12), c.776G>A/p.G259E, c.374dupG (p. Cys125TrpfsTer23) and c.682_683delCT (p. Leu228AspfsTer49), which were commonly homozygous mutations. Among these mutations, c.800C>T (p. Ser267Phe) as a predominant variant accounting for 94.50% of all mutated alleles^[4], and c.263T>C (p. Ile88Thr) as a secondary one. In addition, SLC10A1 genetic variants could also be composed of compound heterozygotes, such as c.800C>T (p.S267 Phe) and c.263T>C (p.I88T), which were rarely reported. According to the literature and the case we provided, no matter the homozygous or heterozygous mutation of c.800C>T (p.S267 Phe) and/or c.263T>C (p.I88T) in SLC10A1 gene, it will lead to NTCPD and induce the phenotype of persistent hypercholesterolemia. However, knowledge about the laboratory and clinical presentations of patients with NTCPD remains rather limited, and the co-occurrence of several autosome hereditary diseases in one case is unusual. To date, there has been no report of NTCPD complicated with other autosomal diseases, such as Thalassemia or/and CSS.

Thalassemia is a group of inherited autosomal recessive hemolytic anemia disease with varied phenotype, which is caused by human globin gene synthesis disorders^[5], including α-Thalassemia and β-Thalassemia. In Chinese populations, α-Thalassemia is mainly caused by three types of genotypes: Southeast Asian deletion (–^SEA deletion), the right deletion (-α^3.7), and the left deletion (-α^4.2). Southeast Asian deletion is the main α-Thalassemia genotype, and the heterozygous deletion (–^SEA/αα) genotype accounts for approximately 66.0 of all the α-Thalassemia mutation carriers^[6].

ARID1A harbors an Nterminal DNA-binding ARID domain and a C-terminal folded region, and as one of the six genes (ARID1A, ARID1B, SMARCA4, SMARCB1, SMARCE1), encodes for the BRG1/BRM-associated factor chromatin remodeling complex^[7]. As a subunit of the evolutionarily, ARID1A plays an important role in the maintenance of cell identity and the determination of cell fate, and is associated with a wide array of developmental disorders and cancers, such as CSS and hepatoblastoma. Approximately 5–7% of molecularly-confirmed CSS was caused by the heterozygous missense variants of ARID1A^[8], such as c.5954C>G (p.Ser1985Cys), c.6314C>T (p.Thr2105Ile), c.6334C>T (p.Leu2112Phe), and c.6843G>T (p.Leu2281Phe). The case we reported, accompanied by a de novo heterozygous missense variant ARID1A, which has not been described in large population cohorts.

It is worth noting that the clinical features of CSS, especially facial features, there is a wider degree of variation in patients with mutations in ARID1A and ARID1B. Some scholars even divided CSS into two groups: “classic” group with coarse facies, and “variant” group with less coarse, more refined features, including thinner eyebrows and thin vermillion border of the lips^[9]. In our case, the patient and his mother were heterozygous missense mutation in ARID1A, but only the baby had feeding difficulties and PFO at birth, and neither the child nor his mother had any other clinical features of CSS during the 2-year follow-up. Therefore, we summarize some problems. First, changing phenotypes according to age, especially craniofacial features and physical or intellectual development. There was a report that patient had only feeding difficulties at birth and other symptoms gradually presented, but our patient still lacked typical symptoms during his growth. Should we consider it as “variant” CSS? Perhaps as a result of a selection bias for the diagnosis, all reports displayed DD, coarse facial appearance and hypo/aplasia of the fifth digit phalanges/nails. Because of this, these features were considered prerequisite for clinical diagnosis of CSS. Second, NTCPD, Thalassemia and CSS are three hereditary diseases associated with autosome. Due to the early onset age, their clinical symptoms are mild or may be similar to some newborn physiological manifestations, such as jaundice. Even some symptoms of the three diseases overlap with each other, such as development disorders. Therefore, it is difficult to diagnose any of the autosomal inherited diseases based on the atypical symptoms, and requires a high level of suspicion for a comprehensive evaluation. In recent years, genetic testing plays an important role in the diagnosis of hereditary diseases. However, it is difficult to find other coexisting hereditary diseases by detecting only one gene mutation site, and hard to carry out whole-gene screening for most patients. Third, due to reports of CSS probands with or without a mildly affected parent, both autosomal recessive and autosomal dominant inheritance have been suggested. But the recessive carrier of ARID1A genetic mutation, like our patient’s mother, has not been reported. The main reasons are attributed to the small number of cases with ARID1A mutations and the incomplete clinical assessment and examinations.

At present, as three genetic diseases, there are no good cure, mainly rely on symptomatic and supportive treatment. Thus, can we learn from the prevention and control strategy of Thalassemia to intervene with NTCPD and CSS? Primary prevention is to reduce the occurrence of congenital disorders and fetus’s disabilities, through health education and genetic screening before pregnancy and in the early stage of pregnancy. Secondary prevention is the treatment of birth defects diagnosed as intermedia or major at an early stage^[10].